Roche Holding AG (OTCMKTS:RHHBY) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Roche Holding AG (OTCMKTS:RHHBY) have been given an average rating of “Hold” by the ten ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $57.00.

RHHBY has been the subject of a number of research analyst reports. The Goldman Sachs Group raised shares of Roche from a “sell” rating to a “hold” rating in a research report on Thursday, January 15th. TD Cowen reissued a “hold” rating on shares of Roche in a research report on Tuesday, February 10th. Morgan Stanley restated an “underweight” rating on shares of Roche in a research note on Wednesday, February 4th. Citigroup began coverage on shares of Roche in a research note on Tuesday, January 27th. They issued a “buy” rating on the stock. Finally, JPMorgan Chase & Co. upgraded shares of Roche from an “underweight” rating to a “neutral” rating in a research report on Monday, December 8th.

Roche Price Performance

Shares of OTCMKTS RHHBY opened at $55.39 on Monday. The company has a current ratio of 1.38, a quick ratio of 1.12 and a debt-to-equity ratio of 0.72. Roche has a 12 month low of $34.75 and a 12 month high of $60.85. The stock has a 50 day moving average of $55.93 and a 200-day moving average of $48.69.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Curio Wealth LLC bought a new position in Roche during the 3rd quarter worth $25,000. Oakworth Capital Inc. bought a new stake in shares of Roche in the third quarter valued at about $57,000. First Horizon Advisors Inc. grew its stake in shares of Roche by 81.2% in the second quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company’s stock valued at $75,000 after acquiring an additional 826 shares in the last quarter. Salomon & Ludwin LLC grew its stake in shares of Roche by 256.6% in the third quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company’s stock valued at $129,000 after acquiring an additional 2,053 shares in the last quarter. Finally, Atlas Capital Advisors Inc. bought a new position in Roche during the fourth quarter worth about $192,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.